Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results
Date:9/22/2011

CRANBURY, N.J., Sept. 22, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications and PL-3994 for acute asthma and other indications, today announced results for its fourth quarter and fiscal year ended June 30, 2011.  

Recent Highlights

  • Palatin initiated enrollment in its Phase 2B trial with bremelanotide in premenopausal women with female sexual dysfunction.
  • Palatin announced commencement of a Phase 1 trial of AZD2820, under development for treatment of obesity, in collaboration with AstraZeneca.
  • In March 2011, Palatin closed on a $23.0 million firm commitment public offering consisting of 23 million units at a price to the public of $1.00.  Net proceeds to Palatin after deducting underwriting discounts and other offering expenses were $21.0 million.

  • Fourth Quarter and Fiscal Year End 2011 ResultsPalatin reported a net loss of $3.3 million, or $(0.09) per basic and diluted share, for the quarter ended June 30, 2011, compared to a net loss of $4.2 million, or $(0.40) per basic and diluted share, for the same period in 2010.The change in net loss for the quarter ended June 30, 2011 compared to the net loss for the quarter ended June 30, 2010 was primarily attributable to $1.3 million of non-cash, non-operating income, which represents the decrease in estimated fair value of the warrant liability from March 31, 2011 through May 11, 2011, the date the warrants ceased to be classified as a liability upon stockholder approval of the increase in authorized common stock

    Palatin's net loss for the year ended June 30, 2011 was $12.8 million, or $(0.64) per basic and diluted share, compared to a net loss of $1.8 million, or $(0.18) per basic and diluted share, for the year ended June 30, 2010.  

    The change in net lo
    '/>"/>

    SOURCE Palatin Technologies, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
    2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
    3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
    4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
    5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
    6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
    7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
    8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
    9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
    10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
    11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/1/2015)... and NEW YORK CITY ... -- As a leading provider of market research reports and ... Worldwide, LLC, indicating that 2015 will be a year of ... For executives operating a stem cell company or cord ... difficult task. You must analyze market conditions, predict industry trends, ...
    (Date:3/31/2015)... March 31, 2015 CytoSorbents Corporation (NASDAQ ... blood purification to treat critically-ill and cardiac surgery ... summary and reports financial results for the fiscal ... 2014 CytoSorb® product revenues were a record $3.1M, ... 2013 CytoSorb® revenues of $0.8M Highlights for the ...
    (Date:3/31/2015)... Pittcon 2015, the 66th Conference and Exposition ... 12, in New Orleans with an economic impact to ... the New Orleans Convention and Visitor's Bureau. This global ... personnel. Those who attended Pittcon for the first-time ... third year, the co-location of Food Labs Conference, organized ...
    (Date:3/31/2015)... NEW YORK , March 31, ... ), a biopharmaceutical company advancing protein biologic therapies ... its Korean marketing partner, Hanmi Pharmaceutical Co., Ltd ... Korea from the country,s Ministry of Food and ... Research Institute (KTR) for MuGard, its oncology supportive-care ...
    Breaking Biology Technology:MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 2MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 3MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 4CytoSorbents Reports Record 2014 Revenue 2CytoSorbents Reports Record 2014 Revenue 3CytoSorbents Reports Record 2014 Revenue 4CytoSorbents Reports Record 2014 Revenue 5CytoSorbents Reports Record 2014 Revenue 6CytoSorbents Reports Record 2014 Revenue 7CytoSorbents Reports Record 2014 Revenue 8CytoSorbents Reports Record 2014 Revenue 9CytoSorbents Reports Record 2014 Revenue 10CytoSorbents Reports Record 2014 Revenue 11Pittcon 2015 Hits the Big Easy in a Big Way 2Pittcon 2015 Hits the Big Easy in a Big Way 3Pittcon 2015 Hits the Big Easy in a Big Way 4PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 2PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 3
    ... a robotic jellyfish, named Robojelly, which not only exhibits characteristics ... could, theoretically at least, never run out of energy thanks ... a set of smart materials, which have the ability to ... and carbon nanotubes, Robojelly is able to mimic the natural ...
    ... are brighter now thanks to a new study by ... Berkeley National Laboratory (Berkeley Lab). Working at the Lab,s ... provided the first experimental determination of the pathways by ... organic thin film. Their results also show how such ...
    ... ("AVX") is pleased to report that it has been selected as ... the Best Early-Stage Vaccine Biotech Company. The award will be announced ... AVX is pleased to be both included in ... as well as being recognized as a leader in the field. ...
    Cached Biology Technology:Jellyfish inspires latest ocean-powered robot 2Better organic electronics 2Better organic electronics 3
    (Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... campaign on CNBC television starting March 30 th . ... airing in New York markets. ... "We are excited about our new ad campaign following the ...
    (Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... wallet is one of the products featured in 2015 ... 20th at 11:00 PM EST on the DIY Network. ... Las Vegas , site of the ...
    (Date:3/18/2015)... , March 18, 2015 As mobile ... new revolutionary smart wallets and apps continue to be introduced ... entrenched in the mobile payment industry in focus today are:  ... Ltd. (NYSE: BABA ), Apple Inc. (NASDAQ: ... and Facebook Inc. (NASDAQ: FB ) ...
    Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6
    ... succeeded in mapping the unique patterns of neural activity ... skunk, fish, urine, musk, and chocolate. Revealing these distinct ... significant step in understanding how the brain translates complex ... perception in the brain, the researchers said. , The ...
    ... Thirty to fifty percent of the global conversion of nutrients ... of the National Academy of Science of the United States ... state that this conversion is not carried out by denitrifying ... Nitrogen compounds act as fertilizers and are the ecological basis ...
    ... has been discovered by a team of researchers at Penn ... another tumor suppressor to control tissue growth. The team's genetic ... 2005 issue of the journal Cell. "This discovery extends our ... development and during the formation of tumors, and it raises ...
    Cached Biology News:Genpathway and Baylor College of Medicine Identify New Genes in Breast Cancer 2Genpathway and Baylor College of Medicine Identify New Genes in Breast Cancer 3Genpathway and Baylor College of Medicine Identify New Genes in Breast Cancer 4Anammox bacteria produce nitrogen gas in oceans' snackbar 2Anammox bacteria produce nitrogen gas in oceans' snackbar 3New tumor-suppressor gene discovered 2New tumor-suppressor gene discovered 3New tumor-suppressor gene discovered 4
    ...
    ... Plate is a 96-well ELISA-compatible plate (containing 12 ... Fiber Monoclonal Antibody is immobilized by a method ... recognizes the tail fiber protein of the T7 ... of 10 9 phage per well and ...
    ... The DNA Engine Dyad instrument is the ... Featuring MJ's world-class thermal performance, the ... display, as well as point-and-click navigation via ... Dyad can be easily and economically expanded ...
    ... Distributed exclusively by BioLegend, the Quansys ... for multiplex analysis of cytokines/chemokines for human, ... Cytokine Array is a fully quantitative ELISA-based ... been absorbed to each well of a ...
    Biology Products: